Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for COVID-19
IRCT20171105037262N4Phase 3Completed
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-blind trial of adalimumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Baqiyatallah University of Medical Sciences. Primary endpoint: Disease severity. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20171105037262N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171105037262N4.